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Abstract
Bacteria associated with mammals are a rich source of microbial biodiversity; however, little is known concerning the
abilities of these microbes to generate secondary metabolites. This report focuses on a bacterium isolated from the ear of a
feral hog from southwestern Oklahoma, USA. The bacterium was identified as a new strain (PE36) of Brevibacillus latersporus,
which was shown via genomic analysis to contain a large number of gene clusters presumably involved in secondary
metabolite biosynthesis. A scale-up culture of B. latersporus PE36 yielded three bioactive compounds that inhibited the
growth of methicillin-resistant Staphylococcus aureus (basiliskamides A and B and 12-methyltetradecanoic acid). Further
studies of the isolate’s secondary metabolome provided both new (auripyrazine) and previously-described pyrazine-
containing compounds. In addition, a new peptidic natural product (auriporcine) was purified that was determined to be
composed of a polyketide unit, two L-proline residues, two D-leucine residues, one L-leucine residue, and a reduced L-
phenylalanine (L-phenylalanol). An examination of the genome revealed two gene clusters that are likely responsible for
generating the basiliskamides and auriporcine. These combined genomic and chemical studies confirm that new and
unusual secondary metabolites can be obtained from the bacterial associates of wild mammals.
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Introduction
Nature has served as a valuable source of bioactive compounds
with many natural products (secondary metabolites) having
entered into clinical use [1]. The sustained successful application
of microbes, plants, and marine life for the identification of new
and inspiring secondary metabolites is a testament to their
immense biological and chemical diversity [1]. Bioactive sub-
stances with unique chemical features have been discovered from a
multitude of organisms inhabiting terrestrial and marine environ-
ments. In order to maintain a rich pipeline for secondary
metabolite discovery, researchers must continue to direct efforts
toward exploring previously unexploited biological resources [2].
The microbial associates of animals, especially those from
vertebrate hosts, represent a virtually untapped source of bacterial
and archaeal diversity [3,4]. These microorganisms participate in
a range of transient and long-term (i.e., symbiotic) relationships
with animal hosts [5]. The spectrum of habitats afforded by the
abundance of discrete microenvironments in and on a mammal’s
body substantially increases the variety of microbial species that
can inhabit a single animal [6,7,8]. Bacteria associated with other
microorganisms, plants, nematodes, insects and sponges produce
an intriguing variety of secondary metabolites [9,10]; however,
relatively little is known about the natural products generated by
the microbes associated with wild mammals. In contrast, mammals
such as humans and domesticated animals host a large microbial
population with some members engaged in the production of
secondary metabolites [11]. Secondary metabolites isolated from
microbes associated with the human body have been shown to
exhibit antibiotic [12], cytotoxic [13], anti-biofilm [14,15], and
anti-tumor [16] properties. Therefore, it is reasonable to expect
that bacteria associated with wild mammals will also be capable of
generating secondary metabolites.
This report describes the use of an opportunistic sampling
approach [17] to access secondary metabolites produced by a
bacterium obtained from the ear canal of a wild mammal. A new,
natural-product-producing strain of Brevibacillus laterosporus was
obtained from a feral hog originating in southwestern Oklahoma,
USA. The natural product biosynthetic potential of this isolate was
revealed using a combination of LC-MS, bioassays, and genomic
data. These efforts provided several compounds including a new
and unusual peptidic metabolite, auriporcine (6); a new pyrazine,
auripyrzine (5); and the previously described antifungal metabo-
lites basiliskamides A and B (1 and 2, respectively). This research
highlights how the integrated application of genomics and
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e90124
metabolomics presents an opportunity for mining new natural
products from bacteria associated with wild mammals.
Results and Discussion
Using an opportunistic sampling approach [17], the oral cavity,
ear canal, and nasal cavity of a feral hog taken by a hunter in
southwestern Oklahoma were swabbed for microbial inhabitants
within 24 h of being bagged. The samples were spread onto agar-
based media and over 160 bacterial colonies were streaked onto
fresh plates. Isolates exhibiting homogenous morphologies were
arrayed onto new plates, incubated for several days, and agar
overlays seeded with methicillin-resistant Staphylococcus aureus were
applied over the surfaces of the plates. A number of isolates
exhibited antibiosis toward S. aureus as demonstrated by zones of
inhibition devoid of visible growth of the pathogen in the overlay
layer (Figure 1). Several of the active bacteria from the hog’s ear
exhibited the same phenotypic characteristics (small to medium
colony size with dark yellow-orange pigmentation) (Figure 1) and
one representative isolate (PE36) was selected for further
investigation.
Genomic analysis of isolate PE36 yielded a total of 16.75 million
reads or 2.49 Gbp with 99.8 percent of reads passing quality
filtering (.Q30 across a sliding window of 50 bp). A total of 63
scaffolds with a genome size of 5.14 Mbp were obtained upon
assembly. These scaffolds had an N50 of 155.81 Kbp and a
maximal scaffold length of 457.91 Kbp producing a near-
complete genome assembly (489-fold coverage). After annotation,
4,791 coding sequences were split between 430 subsystems along
with 100 RNAs. The complete 16S small subunit rRNA sequence
was used to identify isolate PE36 as a member of the family
Paenibacillaceae and the genus Brevibacillus (Figure 2A). A
sequence-based comparison was conducted between the genomes
of strain PE36 and the other sequenced Brevibacillus laterosporus
strains (LMG15441, GI-9, and DSM 25). The genome of
Brevibacillus phR was included due to its close and unresolved
phylogenetic relationship among strains of B. laterosporus. This
analysis warranted the designation of PE36 as a separate strain of
B. laterosporus (Figure 2B) and its genome was submitted to the
NCBI GenBank (accession number NZ_AXBT00000000). The
genome of B. laterosporus strain PE36 was evaluated in the
secondary metabolite analysis pipeline antiSMASH [18] revealing
32 possible biosynthetic gene clusters. This included 11 non-
ribosomal peptide synthase (NRPS) clusters, two polyketide
synthase (PKS) clusters, and four hybrid pathways (Table 1).
A scale-up culture of B. laterosporus PE36 was prepared for the
purification and structure characterization of its natural products.
Silica flash chromatography, C18 vacuum liquid chromatography
(VLC), and preparative and semi-preparative C18 reversed-phase
high performance liquid chromatography (RP-HPLC) were used
to purify the metabolites (Figure 3) responsible for the extract’s
biological activities. This yielded two bioactive (antibacterial)
fractions. The first active fraction was determined to contain
basiliskamides A (1) and B (2) [19], the structures of which were
Figure 1. Antimicrobial overlay plate for detecting organisms
from the feral hog ear that inhibited S. aureus growth. Bacterial
isolates were streaked in ‘‘X’’ shaped patterns onto half-strength TSA
agar. The B. laterosporus PE36 isolate used in this investigation is
indicated by the arrow.
doi:10.1371/journal.pone.0090124.g001
Figure 2. Phylogeny of B. laterosporous PE36 and several related
B. laterosporous isolates. Phylogeny is depicted by (A) maximum
likelihood of 16S rRNA gene sequences and (B) a consensus network
based on whole genome comparisons. Bootstrap values .70% are
listed for nodes in the maximum likelihood tree with the scale bar
representing 0.05 substitutions per position. Branch lengths for the
genome consensus network are proportional to the number of likely
inversion events of least collinear blocks inferred by Mauve.
doi:10.1371/journal.pone.0090124.g002
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confirmed by high-resolution electrospray ionization mass spec-
trometry (HRESI-MS) and ultraviolet (UV) spectroscopy, as well
as one-dimensional proton nuclear magnetic resonance spectros-
copy (1H NMR) and two-dimensional (2D) heteronuclear single
quantum coherence spectroscopy (1H-13C HSQC) data. Com-
pounds 1 and 2 exhibit potent antifungal activities and modest
antibacterial properties [20]. These compounds were previously
reported to have been produced by a strain of Brevibacillus
associated with a marine tubeworm collected in Papua New
Guinea [19]. The active component from the second active
fraction was identified by gas-chromatography-mass-spectrometry
(GC-MS) and 1H NMR as 12-methyltetradecanoic acid (3) [21].
To further probe the chemical diversity of the B. laterosporus
PE36 metabolome, two additional fractions that lacked antibac-
terial activities were selected for chemical analysis. Liquid-
chromatography-mass-spectrometry (LC-MS) profiling of the first
inactive fraction revealed the presence of two compounds
possessing similar UV absorbance spectra (lmax ,220). One of
the compounds was identified as 2,5-bis(3-indolylmethyl)pyrazine
(4), whereas the second compound (5) is reported here for the first
time as a natural product. High resolution ESI-MS analysis of
compound 5 yielded a molecular ion at m/z 222.1039 [M-H]-,
which substantiated a molecular formula of C14H13N3. The
1H
and 13C NMR data for compound 5 were very similar to those
obtained for compound 4 (Table 2). Analysis of the 1H NMR data
revealed a broad exchangeable singlet at dH 10.9, two downfield
singlets at dH 8.32 and 8.36, five aromatic protons (dH 7.22 –
6.94), a singlet integrating for two hydrogens at dH 4.17, and a
methyl singlet at dH 2.45. These features could be accounted for if
one of the two indoles attached to the pyrazine in compound 4 was
replaced by a methyl group in compound 5. The proposed
Table 1. Secondary metabolite biosynthetic gene clusters identified by antiSMASH.a
Cluster # Type Contig # Location Length (bp)
1 Bacteriocin 38 80488 - 94436 13948
2 NRPS 53 1 - 40768 40767
3 NRPS/T1PKS/terpene 54 1 - 33107 33106
4 NRPS 11 26348 - 87628 61280
5 NRPS 11 37970 - 121360 83390
6 Possible gene cluster 11 125350 - 145149 19799
7 Possible gene cluster 27 47359 - 64591 17232
8 Possible gene cluster 12 80286 - 110252 29966
9 Possible gene cluster 34 48 - 5440 5392
10 Siderophore 1 96334 - 110033 13699
11 Bacteriocin/T2PKS/NRSP/trans-AT PKS 30 1 - 98694 98693
12 Trans-AT PKS 20 82148 - 145314 63166
13 Other 48 1 - 24930 24929
14 NRPS 19 1 - 73884 73882
15 NRPS/trans-AT PKS 19 2773 - 124967 122194
16 Possible gene cluster 3 131911 - 144532 12621
17 NRPS 21 1 - 39457 39456
18 Bacteriocin 32 49076 - 61013 11937
19 Possible gene cluster 4 5209 - 19315 14106
20 Possible gene cluster 4 248519 - 260263 11744
21 Possible gene cluster 10 31262 - 47534 16272
22 NRPS 10 154721 - 205832 51111
23 NRPS 25 18455 – 82131 63676
24 NRPS 7 1 - 36763 36762
25 NRPS 7 62273 - 99504 37231
26 NRPS/trans-AT PKS 8 27546 - 139639 112093
27 T3PKS 8 293580 - 334635 41055
28 NRPS 2 8150 - 97503 89353
29 NRPS 16 32087 - 127019 94932
30 Possible gene cluster 14 480 - 9230 8750
31 Phosphonate 14 159394 - 200281 40887
32 Possible gene cluster 14 229110 - 233512 4402
aSecondary metabolite gene clusters predicted by the antiSMASH platform. Gene clusters with strong homologies to families of known biosynthetic gene cluster types
are tentatively assigned (e.g., NRPS, etc.). Gene clusters with biosynthetic characteristics lacking well defined similarities to known types of biosynthetic gene clusters are
labeled ‘‘Possible gene cluster.’’ NRPS: nonribosomal peptide synthetase, PKS: polyketide synthase, T1PKS: type I PKS, T2PKS: type II PKS, T3PKS: type III PKS.
doi:10.1371/journal.pone.0090124.t001
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structural change was subsequently confirmed by 2D NMR to
establish the structure of auripyrazine (5).
HRESI-MS analysis of compound 6 provided a molecular ion
with m/z 799.5330 [M+H]+, which indicated that the compound
had a molecular formula of C43H70N6O8. An initial inspection of
the 1H NMR data revealed that compound 6 was likely peptidic in
nature with signals characteristic of amide doublet protons, as well
as amino-acid a-hydrogen spins (Table 3). Further inspection of
the 1D and 2D NMR data revealed the occurrence of many more
signals than could be accounted for by the proposed molecular
formula; however, additional attempts at purification of the
compound by analytical RP-HPLC were unsuccessful. We also
observed by 1H NMR that the relative distribution of these spins
was not appreciably altered by switching to different solvents (i.e.,
DMSO-d6, acetone- d6, CDCl3, MeOH-d4, and pyridine-d5) or
upon changes to the NMR probe temperature. Therefore, we
conjectured that compound 6 might exist in two dominant
conformational states (Table 3) that were relatively insensitive to
the influence of the surrounding solvent.
Analysis of the data from 2D proton total correlation
spectroscopy (1H-1H TOCSY), 2D gradient heteronuclear multi-
ple bond correlation spectroscopy (1H-13C gHMBC), and 2D
nuclear Overhauser effect spectroscopy (1H-1H NOESY) exper-
iments provided evidence for several discrete spin systems
attributable to two proline and three leucine residues that were
linked to form a peptidic Pro-Leu-Pro-Leu-Leu fragment. Another
spin set was probed in greater detail with 1H-13C gHMBC leading
to the generation of a six carbon fragment in which two of the
carbon atoms were attached to oxygen atoms (dC 172.0 and 72.5,
amide carbonyl and a hydroxyl-group-bearing methine, respec-
tively) (Figure S1). Examination of the 1H-13C gHMBC data
helped link this fragment to the peptide portion of the new
metabolite (Figure S1). The placement of this six carbon fragment
at the N-terminus of the peptide was further supported by a one-
bond proton-nitrogen heteronuclear correlation (1H-15N HSQC)
experiment from which we found no evidence for primary amide
hydrogens. The remaining carbon atoms in compound 6 were
determined to comprise a phenylalaninol residue (Pho) at the C-
Figure 3. Structures of secondary metabolites isolated from B. latersporus PE36.
doi:10.1371/journal.pone.0090124.g003
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terminus of the peptide (Figure S1). The reduction of the L-
phenylalanine carboxyl group to a primary alcohol was confirmed
by the presence of a carbon chemical shift at dC 62.4 for the atom
bearing the primary alcohol. A series of MSn experiments (Table 4)
were performed to provide additional substantiation for the
proposed planar structure of compound 6. A majority of the
fragment ions exhibited a loss of water and/or putative
intramolecular cyclization as reported for similar structures [22].
Several of the fragments were generated through cleavage of the
amide bonds, thus confirming the proposed sequence of amino
acid residues in compound 6.
The relative configuration of compound 6 was determined by
X-ray diffraction experiment on a single crystal prepared in a
vapor diffusion chamber (acetone and ether) (Table S1).
Compound 6 exhibited a helix-like conformation in the crystalline
state with the leucine residue side chains projecting outward from
the compound in a relatively disordered state (Figure 4). We
observed a 3S*,5S*,7S*,12R*,18S*,23R*,29S*,35S* relative con-
figuration for 6, which indicated that some of the incorporated
amino acid residues possessed a D-configuration. Marfey’s analysis
[23] was subsequently carried out demonstrating that both of the
proline residues were L-configured (Figure S2). In contrast, we
detected a ,2:1 mixture of D- and L-leucines, respectively, using
the Marfey’s derivatization method. This was in agreement with
the proposed 12R*, 23R*, 29S* assignments for the three leucine
residues as determined by X-ray analysis (Figure S2). The
Marfey’s analysis also provided definitive evidence for the presence
of L-phenylalaninol (Figure S2). Thus, the absolute configuration
of compound 6 was determined to be 3S,5S,7S,12R,18S,23R,
29S,35S.
The genome of B. laterosporus PE36 was reexamined to provide a
link between the secondary metabolites made by this isolate and
their respective biosynthetic genes. Of the 11 NRPS gene clusters
identified in PE36 (Table 1), cluster 23 (Figure 5A) exhibited
several distinctive features making it the likely source of compound
6. Namely, cluster 23 contains an initial PKS-like initiation
Table 2. 1H (500 MHz) and 13C (125 MHz) NMR data (DMSO-
d6, 25uC) for auripyrazine (5).
Position 13C, typea 1H (J in Hz)
2 123.7, CH 7.22, m
3 111.1, C -
4 125.7, C -
5 136.1, C -
6 111.2, CH 7.33, d (8.2)
7 119.0, CH 6.94, m
8 119.0, CH 7.48, m
9 121.5, CH 7.06, m
10 31.3, CH2 4.17, s
11 155.4, C -
13 142.3, CH 8.32, s
14 152.3, C -
16 141.6, CH 8.35, s
17 21.8, CH3 2.45, s
1-NH - 10.92, brs
a 13C data were obtained via inverse detection 1H-13C HSQC and 1H-13C gHMBC
experiments.
doi:10.1371/journal.pone.0090124.t002
Table 3. 1H (500 MHz) and 13C (125 MHz) NMR data (DMSO-
d6, 25uC) for the two predominant solution conformers of
auriprocine (6).
Residue Position Conformer 1 Conformer 2
13Ca 1H 13Ca 1H
SCFb 1 11.1, CH3 0.82 11.1, CH3 0.82
2 22.8, CH2 1.52, m;
1.06, m
22.8, CH2 1.51, m; 1.08, m
3 37.1, CH 1.66, m 37.1, CH 1.67, m
4 15.0, CH3 0.86, m 15.0, CH3 0.86, m
5 72.5, CH 3.91, m 72.5, CH 3.94, m
6 172.6, C - 172.6, C -
L-Pro 7 59.1, CH 4.84, m 59.1, CH 4.82, m
8 31.5, CH2 2.09, m 31.5, CH2 2.09, m
9 28.5, CH2 1.75, m 28.5, CH2 1.75, m
10 46.2, CH2 3.41, m 46.2, CH2 3.41, m
11 171.9, C - 171.9, C -
D-Leu NH - -
12 51.3, CH 4.35, m 51.3, CH 4.36, m
13 39.9, CH2 1.45, m 39.6, CH2 1.25, m
14 23.9, CH 1.53, m 23.7, CH 1.47, m
15 20.8-23.0, CH3 0.86, m 20.8-23.0,
CH3
0.76, m
16 20.8-23.0, CH3 0.76, m 20.5, CH3 0.66, m
17 170.9-172.2 - -
L-Pro 18 60.0, CH 4.25, m 59.7, CH 4.34, m
19 28.9, CH2 2.05, m 28.9, CH 2.05, m
20 24.1, CH2 1.78, m;
1.91, m
24.1, CH2 1.78, m; 1.91, m
21 46.4, CH2 3.67, m;
3.48, m
46.4, CH 3.65, m; 3.50, m
22 171.6 - 171.6 -
D-Leu NH - 7.83, m - 7.84, m
23 48.6, CH 4.53, m 51.5, CH 4.17, m
24 39.6, CH2 1.45, m 39.6, CH2 1.48, m
25 23.6, CH 1.56, m 23.6, CH 1.51, m
26 20.8-23.0, CH3 0.87, m 20.8-23.0,
CH3
0.82, m
27 20.8-23.0, CH3 0.87, m 20.8-23.0,
CH3
0.87, m
28 170.3, C - 170.9-172.2,
C
-
L-Leu NH - 8.00, d
(8.3)
- 8.15, m
29 51.6, CH 4.15, m 50.6, CH 4.21, m
30 40.9, CH2 1.41, m 40.0, CH 1.38 m
31 23.7, CH 1.50, m 23.7, CH 1.45, m
32 20.8-23.0, CH3 0.84, m 20.8-23.0,
CH3
0.86, m
33 20.8-23.0, CH3 0.78, m 20.8-23.0,
CH3
0.79, m
34 170.9-172.2, C - 170.9-172.2,
C
-
L-Pho NH - 7.57, d
(8.8)
- 7.67, d (8.3)
35 52.6, CH 3.86, m 52.6, CH 3.86, m
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module that is postulated to be responsible for loading the non-
amino acid starter unit at the compound’s N-terminus. This is
followed by NRPS modules containing adenylation domains that
are predicted to sequentially incorporate proline R leucine R
proline R leucine R isoleucine R leucine R tyrosine R leucine
R isoleucine R threonine. The observed order of amino acids in
compound 6, L-prolineR D-leucineR L-prolineR D-leucineR
L-leucine R L-phenylalaniol, fits reasonably well with this
prediction. Upon closer inspection, epimerization domains were
identified as being associated with each of the predicted leucine
incorporation steps. This explains the D-configurations of the first
two leucines. In contrast, the L-configuration of the third leucine is
hypothesized to have resulted from an inactive epimerization
domain or the leucine incorporation module is skipped and the
downstream isoleucine incorporation module that lacks an
epimerization domain installs the final leucine. The termination
of the NRPS chain at the tyrosine/phenylalanine residue could
occur via several scenarios including 1) phenylalanine incorpora-
tion followed by termination and post-production reductive
tailoring; 2) tyrosine incorporation followed by termination,
dehydroxylation, and reduction; or 3) full incorporation of all
the predicted amino acids followed proteolysis of a tyrosine/
phenylalanineR leucine bond and reduction. Based on the order
of amino acid residues predicted by antiSMASH analysis and
presence of appropriate modifying features (i.e., epimerization
domains), putative biosynthetic gene cluster 23 is most likely
responsible for the production of 6; however, further experiments
will be needed to confirm this hypothesis.
The antiSMASH data were also probed to determine the
probable gene cluster responsible for the production of the
basiliskamides (1 and 2). Focusing on the only two gene clusters
predicted to be predominatly composed of PKS-related domains
(Table 1), we propose that biosynthetic cluster 12 is the most likely
candidate for the production of compounds 1 and 2. Cluster 12 is
predicted to be a trans-AT PKS, which also contains an NRPS-like
domain. The trans-AT PKSs are architecturally and biosyntheti-
cally unique in a number of key ways [24]. Most notably, none of
the individual modules in a trans-AT PKS contain a dedicated AT
(acetyltransferase) domain. Instead the modules receive carbon
building blocks from a shared AT, which in this case is a fused
tandem AT domain [25]. Figure 5B illustrates the genomic
organization of the proposed biosynthetic gene cluster and a
plausible biosynthetic pathway responsible for the generation of
compounds 1 and 2. The starter unit is loaded by a predicted
acetyl-loading AT of the GCN5-related superfamily (GNAT) [26].
Each ketosynthase domain (KS) is expected to use malonyl-CoA to
build the polyketide chain. Ketoreductases (KR), enolreductases
(ER), and methyl transferases (MT) serve to further derivatize the
polyketide. The fourth module is split with a domain configuration
Table 4. MSn fragments used to support the planar structure
of auriprocine (6).a
Fragment Parent ions, m/z Fragment m/z
[SCF-Pro-Leu-Pro-Leu]+ 799, 781 535
[SCF-Pro-Leu-Pro]+ 799, 781, 535 422
[Pro-Leu-Leu-Pho]+ + 2H 799, 781 457
[Leu-Leu-Pho]+ + 2H 799, 781, 457 360
[Leu-Pho]+ + 2H 799, 781, 457 247
aThe m/z of the parent ion of each fragment is shown. SCF: N-terminal six
carbon fragment, Pho: phenylalaniol.
doi:10.1371/journal.pone.0090124.t004
Table 3. Cont.
Residue Position Conformer 1 Conformer 2
13Ca 1H 13Ca 1H
36 62.4, CH 3.30, m;
3.25,m
62.36, CH 3.29, m; 3.21, m
37 36.5, CH 2.86, m;
2.67, m
36.5, CH 2.85, m; 2.65, m
38 139.0, C - 139.0, C -
39 128.6, CH 7.21, m 128.6, CH 7.21, m
40 127.7, CH 7.25, m 127.7, CH 7.25, m
41 125.5, CH 7.17, m 125.5, CH 7.14, m
42 127.7, CH 7.25, m 127.7, CH 7.25, m
43 128.6, CH 7.21, m 128.6, CH 7.21, m
a 13C data were obtained via inverse detection by 1H-13C HSQC and 1H-13C
gHMBC experiments. bSCF: six carbon fragment.
doi:10.1371/journal.pone.0090124.t003
Figure 4. Pymol representation of auriprocine (6). Images
generated from X-ray data for 6. The top two images depict the two
opposing faces of the structure, rotated 180u. The bottom image is the
helical wheel representation, viewed from the N-terminus along the
helix axis. An animated image of 6 is provided in Movie S1.
doi:10.1371/journal.pone.0090124.g004
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of KS – KR – ACP – KS – DH – ACP – KR, which is indicative
of type B dehydrating bimodules [25]. These types of modules are
capable of producing double bonds with either the E or Z
configurations [25].
The non-polyketide portions of compounds 1 and 2 are likely
introduced from three additional genes co-located within the gene
cluster. One of these genes was identified as a putative
aminotransferase that could be responsible for converting a
carboxylate into an amide [7]. The cinnamic acid portion of the
molecule could be installed by an NRPS-like adenylation domain.
Adenylation domains have previously been shown to incorporate
non-amino acid moieties into compounds via ester linkages [6,27].
This assessment of gene cluster 12 represents a theoretical basis for
understanding the biosynthetic origins of 1 and 2. Further
experiments including feeding studies, gene knockouts, and other
molecular manipulation approaches will be required to confirm
these hypothetical steps leading to the production of 1 and 2.
The results of these combined chemical and genomic studies
suggest that bacteria associated with wild mammals are a potential
source of unique and bioactive secondary metabolites. Despite the
Figure 5. Interpretation of antiSMASH results and proposed biosynthetic origins of basiliskamides A (1) and B (2) and auriporcine
(6). Panel A illustrates the biosynthetic gene cluster hypothesized to be responsible for the production of 6. Adenylation domains are labeled with
the amino acids they are predicted to contribute. The two domains potentially involved in loading of the L-leucine residues are contained in the
shaded box. The additional domains shaded grey are believed not to be involved in the production of 6 or were incorporated, but later removed from
the metabolite. Panel B shows the organization of the putative basiliskamide gene cluster, as well as a proposed biosynthetic scheme for the
production of the polyketide portions of 1 and 2. The fused, tandem AT domains are separate from the other modules. The dehydrating bimodule is
shown split, as the gene that encodes the two KS domains are separated from the dehydrogenase and ketoreductase. The genes encoding the
predicted aminotransferase, condensation, and adenylation domains (hypothesized to transform the amide and add the cinnamic acid moieties to
the polyketide chain) are labeled. The putative functions of the genes are indicated as A (adenylation), C (condensation), KR (ketoreductase), E
(epimerization), GNAT (GCN5-related acetyltransferase), KS (ketosynthase), ER (enolreductase), MT (methyltransferase), DH (dehydrogenase), and AT
(acetyltransferase).
doi:10.1371/journal.pone.0090124.g005
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promising opportunities revealed through this work, we can only
speculate about the nature of the biological relationship between
B. laterosporus PE36 and feral hogs (e.g., is the bacterium common
to the host or an example of a transient association). Our group
has initiated studies to investigate this and related questions about
the bacteria recovered from the microbiomes of wild mammals.
Nevertheless, our past and current screening efforts involving
other wild mammals and their associated bacteria suggest that
these microbes have tremendous potential for accessing new
dimensions of microbial biodiversity and chemodiversity.
Materials and Methods
General Experimental
UV data were collected on a Hewlett Packard 8452A diode
array spectrophotometer. Optical rotation data were determined
on a Rudolph Research Analytical Autopol III automatic
polarimeter. UV–CD spectra were measured on an AVIV circular
dichroism spectrometer model 202-01. NMR data were obtained
on a Varian VNMR spectrometer (500 MHz). Accurate mass data
were collected on an Agilent 6538 HRESI QTOF MS coupled
with an Agilent 1290 HPLC. LC-MS analyses were performed on
a Shimadzu LC-MS 2020 system (ESI quadrupole) coupled to a
photodiode array detector. The samples were separated using a
Phenomenex Kintex column (2.6 mm C18 column, 100 A˚,
7563.0 mm). The HPLC system utilized SCL-10A VP pumps
and system controller with a Gemini 5 mm C18 column (110 A˚,
250621.2 mm, flow rates of 1 to 10 mL/min). X-ray data were
collected using a diffractometer with a Bruker APEX ccd area
detector and graphite-monochromated Mo Ka radiation
(l= 0.71073 A˚). All solvents were HPLC grade or better.
Collection and Isolation of Bacteria
The mouth, nose, and ears of a feral hog, shot by a hunter (in
compliance with state ordinances) in southwestern Oklahoma, were
swabbed with sterile cotton swabs. Since our opportunistic sampling
strategy does not involve the handling of live animals, only sampling
carcasses, we have been assigned an internal case-tracking number
(R11-021) by the University of Oklahoma IACUC. A State-of-
Oklahoma-issued Scientific Collector Permit (permit #5250) was
obtained for the purpose of sampling carcasses. Permission was
granted to sample the head of the hog carcass; the research team did
not take ownership of the carcass at any time. The tip of each swab
was removed and placed into a sterile 15 mL Falcon tube
containing a 0.9% NaCl (w/v) solution. The tubes were vortexed
and diluted 1:10 with 0.9% NaCl. Aliquots of 50 mL were spread on
half-strength tryptic soy agar (TSA) plates. The plates were
incubated at 37uC under a 5% CO2 atmosphere for two weeks.
Colonies were selected based on morphological uniqueness and re-
streaked on half strength TSA plates until pure, morphologically
homogenous cultures were obtained.
Overlay Assay
Bacterial isolates were arrayed onto half strength TSA plates
and incubated for up to one week. A layer of half strength TSA
seeded with methicillin-resistant S. aureus was applied to the surface
of each plate. The plates were incubated at 37uC under a 5% CO2
atmosphere for five days and periodically examined for zones of S.
aureus inhibition.
DNA Extraction and Sequencing
Genomic DNA was extracted using the PowerBiofilm DNA
Isolation kit (MoBio Laboratories, Carlsbad, CA) by spinning
down 2.0 mL of turbid culture and following the manufacturer
instructions. The purity of gDNA was confirmed by spectro-
photometery (Implen) and submitted to the Oklahoma Medical
Research Foundation genomics core facility for sequencing on an
Illumina MiSeq using TruSeq LT 26150 bp chemistry (Illumina,
San Diego, CA). Reads were assembled using the CLC Genomics
Workbench suite de novo assembly algorithm (CLC Bio, Cam-
bridge, MA). Contigs smaller than 800 bp were discarded. After
assembly, scaffolds were initially submitted to the RAST server for
total-genome annotation [28]. For final annotation, the scaffolds
were submitted to the NCBI PGAP server. RAST annotated
scaffolds were also uploaded to antiSMASH [18] to identify
putative biosynthetic gene clusters associated with the production
of secondary metabolites. Pathways identified by antiSMASH
were amended to the PGAP annotation after submission to
GenBank. Annotated gDNA was deposited with GenBank under
the accession number NZ_AXBT00000000.
Culture Conditions and Extraction
Starter cultures of the bacterium were prepared in tryptic soy
broth (TSB) and shaken on a rotary shaker at 130 rpm at room
temperature for 12 h. For scale-up preparation, 1 L Erlenmeyer
flasks containing 300 mL of sterile TSB were inoculated with
1 mL of starter culture. The flasks were shaken at 130 rpm at
room temperature for 1 week and the cultures were pooled prior to
partitioning. The pooled culture broth with cells was partitioned
three times against EtOAc (1:1 vol/vol) and the solvent removed
from the organic layer under reduced pressure on a rotary
evaporator.
Compound Isolation
The crude extract (,4 g from 30 L culture) was absorbed onto
silica gel and subjected to flash chromatography fractionation
using a hexane-CH2Cl2-MeOH gradient on an Isolera System
(Biotage, Charlotte, NC). The purification of each compound was
achieved as follows:
12-methyltetradecanoic acid (3). Silica flash column chro-
matography was performed (hexane-DCM-MeOH) and the
fraction that eluted with 100% DCM was further separated using
C18 RP-HPLC. A MeOH-H2O gradient (20% MeOH for 5
minutes, 20–100% MeOH gradient over 50 minutes, 100%
MeOH for 10 minutes at a 10 mL/min flow rate) resulted in a
single active fraction. This fraction was purified by semi-
preparative RP-HPLC (60% acetonitrile for 10 minutes, 60–
100% acetonitrile gradient over 45 minutes, 100% acetonitrile for
10 minutes at 2 mL/min) to provide 3 (10 mg). The structure of
the metabolite was determined by 1H NMR and GC-MS analysis.
Basiliskamides A (1) and B (2). C18 VLC (step-gradient of
25:75, 50:50, 75:25, and 100:0 MeOH-H2O) was performed and
the fraction that eluted with 100% MeOH was further separated
by C18 RP-HPLC. A MeOH-H2O gradient (20% MeOH for 5
minutes, 20–100% MeOH gradient over 50 minutes, 100%
MeOH for 10 minutes at a 10 mL/min flow rate) resulted in a
single active fraction. This fraction was further processed by semi-
preparative C18 RP-HPLC (isocratic, 80% MeOH) to yield 1 and
2 (2 and 6 mg, respectively). The compounds were identified
based on comparisons of their experimental and published HR-
ESIMS, UV, and NMR data [19].
2,5-bis(3-indolylmethyl)pyrazine (4). An HPLC fraction
that eluted after 1 and 2 was collected and separated by C18 RP-
HPLC (60% MeOH for 5 minutes, 60–100% MeOH over 50
minutes, 100% MeOH for 10 minutes at a 10 mL/min flow rate)
to provide 4 (7 mg). The structure of 4 was determined by
comparing its HR-ESIMS and 1H NMR data to published values
[29].
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Auripyrazine (5). A fraction obtained prior to the elution of
1 and 2 was collected and fractionated by preparative C18 RP-
HPLC (20% MeOH for 5 minutes, 20–100% MeOH gradient
over 50 minutes, 100% MeOH for 10 minutes at a 10 mL/min
flow rate). Purification by semi-preparative C18 RP-HPLC
(isocratic, 40% acetonitrile with 0.1% formic acid at a 2 mL/
min flow rate) provided 5 (5 mg).
Auriporcine (6). A late eluting fraction from the same C18
RP-HPLC gradient that yielded 1 and 2 was pursued for further
analysis. Semi-preparative C18 RP-HPLC with acetonitrile and
H2O treated with 0.1% trifluoroacetic acid (10% acetonitrile for 5
minutes, 10–100% acetonitrile gradient over 55 minutes at a
2 mL/min flow rate) resulted in the purification of 6 (2 mg).
Marfey’s Analysis
Marfey’s analysis [23] was performed to determine the absolute
configuration of each amino acid contained in 6. Briefly,
approximately 1 mg of 6 was dissolved in 6 M HCl and heated
at 100uC for approximately 18 h. After heating, the sample was
dried under reduced pressure, redissolved in 50 mL of water and
transferred to a 1.5 mL centrifuge tube. Aliquots consisting of
50 mL of 50 mM of the D and L enantiomers of each amino acid
were independently treated in 1.5 mL centrifuge tubes. To each
standard and sample, 100 mL of 1% FDAA and 20 mL of 1 M
NaHCO3 were added. Tubes were capped and heated in a 40uC
water bath with periodic mixing for 1 h. After cooling to room
temperature, 10 mL of 2 M HCl was added to each tube. The
mixtures were dried under reduced pressure and redissolved in
200 mL of 9:1 MeOH-H2O. Samples were diluted further to one
tenth of their original concentration with 9:1 MeOH-H2O prior to
LC-MS analysis.
X-ray Analysis
A colorless prism-shaped crystal of 6 with dimensions
0.4460.1660.12 mm was selected for structure analysis. The
sample was cooled to 100 K. Cell parameters were determined
from a non-linear least squares fit of 6,210 peaks in the range
2.41,h,26.04u. A total of 40,661 data points were measured in the
range 1.554,h,28.344u using Q andv oscillation frames. The data
were corrected for absorption by the empirical method giving
minimum and maximum transmission factors of 0.964 and 0.990.
The data were merged to form a set of 10,800 independent data
with R(int) = 0.0586 and a coverage of 99.9%. The orthorhombic
space group P212121 was determined by systematic absences and
statistical tests and verified by subsequent refinement. The structure
was solved by direct methods and refined by full-matrix least-
squares methods on F2. The positions of hydrogens bonded to
carbons were initially determined by geometry and were refined
using a riding model. Hydrogens bonded to nitrogens and oxygens
were located on a difference map, and their positions were refined
independently. Non-hydrogen atoms were refined with anisotropic
displacement parameters. Hydrogen atom displacement parameters
were set to 1.2 (1.5 for methyl) times the isotropic equivalent
displacement parameters of the bonded atoms. A total of 573
parameters were refined against 118 restraints and 10,800 data to
give wR(F2) = 0.1925 and S = 1.011 for weights of w = 1/[s2 (F2) +
(0.0900 P)2 + 5.0000 P], where P = [Fo2 + 2Fc2]/3. The final R(F)
was 0.0707 for the 9,029 observed, [F.4s (F)], data. The largest
shift/s.u. was 0.012 in the final refinement cycle. The final
difference map had maxima and minima of 0.315 and -0.374 e/
A˚3, respectively. The absolute structure could not be determined by
refinement of the Flack parameter. Further documentation of these
data can be obtained in CIF File S1.
Compound Characterization
Auripyrazine (5): yellow solid; UV (MeOH) lmax 222 (log e
3.49); 1H and 13C NMR data refer to Table 2; HRESI-MS [M-
H]- m/z 222.1039 (calculated for C14H12N3, 222.1031). See
Figures S3–S7 for 1D and 2D NMR, HRESI-MS, and UV data.
Auriporcine (6): white solid; UV (MeOH) lmax 206 (log e
4.19), [a]D (c 0.065) -27.7;
1H and 13C NMR data refer to Table 3;
HRESI-MS [M+H]+ m/z 799.5330 (calculated for C43H71N6O8,
799.5333). See Figures S8-S18, for 1D and 2D NMR data,
thermal ellipsoid plot, HRESI-MS, UV, and CD data. See Movie
S1 for an animated PyMol representation of 6.
Supporting Information
Figure S1 2D NMR correlations used to determine the
planar structure of auriprocine, 6. Important 2D NMR
correlations used in the structure elucidation of 6 are shown:
1H-1H TOCSY (shown as rust colored bonds), 1H-1H NOESY
(illustrated as orange double-headed arrows), and 1H-13C gHMBC
(shown as blue single-headed arrows).
(TIF)
Figure S2 Overlaid selective ion trace chromatograms
showing the C18 LC-MS results of the Marfey’s analysis.
Single ion trace detection of the derivatized amino acids:
derivatized proline (blue), leucine (red), and phenylalaninol
(green).
(TIF)
Figure S3 1H (DMSO-d6, 256C) spectrum of compound
5. Signals resulting from impurities are marked with red dots.
(TIF)
Figure S4 1H-13C HSQC (DMSO-d6, 256C) spectrum of
compound 5. CH groups are shown in blue, CH2 groups are in
red.
(TIF)
Figure S5 1H-13C gHMBC (DMSO-d6, 256C) spectrum of
compound 5.
(TIF)
Figure S6 HRESI-MS (negative mode) data for com-
pound 5.
(TIF)
Figure S7 UV data for compound 5.
(TIF)
Figure S8 1H NMR (500 MHz, DMSO-d6, 256C) spec-
trum of compound 6.
(TIF)
Figure S9 1H-13C HSQC (DMSO-d6, 256C) spectrum of
compound 6. CH groups are shown in blue, CH2 groups are in
red.
(TIF)
Figure S10 1H-13C gHMBC (DMSO-d6, 256C) spectrum
of compound 6.
(TIF)
Figure S11 1H-13C TOCSY (DMSO-d6, 256C) spectrum
of compound 6.
(TIF)
Figure S12 1H-1H gCOSY (DMSO-d6, 256C) spectrum of
compound 6.
(TIF)
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Figure S13 1H-1H NOESY (DMSO-d6, 256C) spectrum of
compound 6.
(TIF)
Figure S14 Overlaid 1H-14N HSCQ (DMSO-d6, 256C)
spectra of compound 6. Overlay of two NMR experiments.
Data from the first experiment, optimized to show NH signals
only, are illustrated in red. Data from the second experiment,
optimized to show both NH and NH2, are illustrated in blue. Data
from both experiments show complete overlap indicating there are
no secondary amines.
(TIF)
Figure S15 Thermal ellipsoid plot of compound 6.
(TIF)
Figure S16 HRESI-MS (positive mode) of compound 6.
(TIF)
Figure S17 UV data for compound 6.
(TIF)
Figure S18 CD data for compound 6.
(TIF)
Table S1 Crystal data and structure refinement data
for compound 6.
(DOCX)
CIF File S1 X-ray coordinate data for compound 6.
(CIF)
Movie S1 Rotating PyMOL representation of compound
6.
(MP4)
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